Currently, various early-stage MSLN-CAR T cell trials are ongoing, covering several malignancies including malignant pleural mesothelioma (MPM), pancreatic cancer, lung cancer and ovarian cancer. This evidence concerns the gene MSLN and lung carcinoma.